A B-Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies.

ABSTRACT:

Background

B-Raf V600E mutations account for about half of all skin cutaneous melanoma cases, and patients with this mutation are sensitive to BRAF inhibitors. However, aberrations in other genes in the MAPK/ERK pathway may cascade a similar effect as B-Raf V600E mutations, rendering those patients sensitive to BRAF inhibitors. We rationalized that defining a signature based on B-Raf pathway activity may be more informative for prognosis and drug sensitivity prediction than a binary indicator such as mutation status.

Methods

In this study, we defined a B-Raf signature score using RNA-seq data from TCGA. A higher score is shown to not only predict B-Raf mutation status, but also predict other aberrations that could similarly activate the MAPK/ERK pathway, such as B-Raf amplif

SUBMITTER: Yao K 

PROVIDER: S-EPMC8855909 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature